Enter Note Done
Go to previous page in this tab
Session
  • Presentation | ePoster Theater - Next Generation Efforts to Prevent Obesity and Type 2 Diabetes
  • ePoster Theater
  • 2094-LB - Electrocardiogram Abnormalities in Relatively Early Type 2 Diabetes—Prevalence and Incidence in the Glycemia Reduction Approaches in Diabetes (GRADE) Cohort [Board No. 2094]
    • Schedule
    Notes
  • 241
    Set Timezone
R.Pop-busui: Advisory Panel; ; Lexicon Pharmaceuticals, Inc, Novo Nordisk, Board Member; ; American Diabetes Association, Consultant; ; Averitas Pharma, Inc, Roche Diagnostics, Other Relationship; ; Biogen, Research Support; ; Bayer Pharmaceuticals, Inc, Juvenile Diabetes Research Foundation (JDRF), Novo Nordisk, National Institute of Diabetes and Digestive and Kidney Diseases. S.Mudaliar: Consultant; ; Sun Pharmaceutical Industries Ltd. D.S.Schade: None. E.R.Seaquist: None. M.Tiktin: None. E.Z.Soliman: None. J.B.Green: Consultant; ; BI Lilly NovoNordisk Bayer Anji Vertex Valo Mineralys AstraZeneca , Research Support; ; BI Lilly Merck Bluedrop Roche. Grade research group: n/a. S.Rosin: None. N.M.Butera: None. H.Krause-steinrauf: None. H.Abou assi: Research Support; ; Novo Nordisk, Stock/Shareholder; ; Gilead Sciences, Inc, Regeneron Pharmaceuticals, Medtronic, Moderna, Inc, MannKind Corporation, Merck & Co., Inc, Pfizer Inc. R.K.Garg: None. S.E.Inzucchi: Consultant; ; Novo Nordisk, AstraZeneca, Boehringer-Ingelheim, Merck & Co., Inc, Pfizer Inc, Bayer Pharmaceuticals, Inc. A.Katona: None. J.B.Mcgill: Advisory Panel; ; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Lilly Diabetes, Novo Nordisk, MannKind Corporation, Consultant; ; Jaeb Center for Health Research, Research Support; ; Diagnode, Lexicon Pharmaceuticals, Inc, Biomea Fusion.
Type
Track
Topic
Main Session